{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T08:05:40Z","timestamp":1784966740597,"version":"3.55.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1097\/rhu.0b013e31823682f5","type":"journal-article","created":{"date-parts":[[2012,12,20]],"date-time":"2012-12-20T06:39:46Z","timestamp":1355985586000},"page":"358-362","source":"Crossref","is-referenced-by-count":69,"title":["Effects of Anti-Tumor Necrosis Factor Agents for Familial Mediterranean Fever Patients With Chronic Arthritis and\/or Sacroiliitis Who Were Resistant to Colchicine Treatment"],"prefix":"10.1097","volume":"17","author":[{"given":"Sule Apras","family":"Bilgen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levent","family":"Kilic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Akdogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sedat","family":"Kiraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umut","family":"Kalyoncu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Karadag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihsan","family":"Ertenli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meral","family":"Calguneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210207","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/sj.ejhg.5200658","article-title":"The spectrum of familial Mediterranean fever (FMF) mutations.","volume":"9","author":"Touitou","year":"2001","journal-title":"Eur J Hum Genet"},{"key":"R2-3-20210207","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/ard.2004.029447","article-title":"Severe disease in patients with rheumatoid arthritis carrying a mutation in the Mediterranean fever gene.","volume":"64","author":"Rabinovich","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R3-3-20210207","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/ard.59.6.428","article-title":"Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study.","volume":"59","author":"Van den Bosch","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"R4-3-20210207","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/art.511","article-title":"Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy.","volume":"46","author":"Van Den Bosch","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R5-3-20210207","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2169\/internalmedicine.46.0064","article-title":"Successful treatment with infliximab and low-dose methotrexate in a Japanese patient with familial Mediterranean fever.","volume":"46","author":"Nakamura","year":"2007","journal-title":"Intern Med"},{"key":"R6-3-20210207","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10067-005-1122-9","article-title":"Familial Mediterranean fever responds well to infliximab: single case experience.","volume":"25","author":"Ozgocmen","year":"2006","journal-title":"Clin Rheumatol"},{"key":"R7-3-20210207","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/art.1780401023","article-title":"Criteria for the diagnosis of familial Mediterranean fever.","volume":"40","author":"Livneh","year":"1997","journal-title":"Arthritis Rheum"},{"key":"R8-3-20210207","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1053\/S0049-0172(03)00137-9","article-title":"Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization.","volume":"33","author":"Lidar","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"R9-3-20210207","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index.","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"R10-3-20210207","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s002960100103","article-title":"Arthritis in familial Mediterranean fever.","volume":"20","author":"Uthman","year":"2001","journal-title":"Rheumatol Int"},{"key":"R11-3-20210207","first-page":"859","article-title":"Arthritis as the sole episodic manifestation of familial Mediterranean fever.","volume":"32","author":"Lidar","year":"2005","journal-title":"J Rheumatol"},{"key":"R12-3-20210207","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10067-008-0980-3","article-title":"The frequency of sacroiliitis in familial Mediterranean fever and the role of HLA-B27 and MEFV mutations in the development of sacroiliitis.","volume":"28","author":"Kasifoglu","year":"2009","journal-title":"Clin Rheumatol"},{"key":"R13-3-20210207","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1182\/blood.V85.12.3586.bloodjournal85123586","article-title":"Cytokine activation during attacks of the hyperimmunoglobulinemia D and periodic fever syndrome.","volume":"85","author":"Drenth","year":"1995","journal-title":"Blood"},{"key":"R14-3-20210207","first-page":"1544","article-title":"Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet's disease. A comparative study with familial Mediterranean fever and healthy subjects.","volume":"20","author":"Mege","year":"1993","journal-title":"J Rheumatol"},{"key":"R15-3-20210207","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10067-002-0682-1","article-title":"Serum sIL-2r, IL-6, IL-10 and TNF-alpha level in familial Mediterranean fever patients.","volume":"22","author":"Baykal","year":"2003","journal-title":"Clin Rheumatol"},{"key":"R16-3-20210207","first-page":"721","article-title":"Effects of colchicine on inflammatory cytokines and selectins in familial Mediterranean fever.","volume":"16","author":"Kiraz","year":"1998","journal-title":"Clin Exp Rheumatol"},{"key":"R19-3-20210207","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(97)09408-7","article-title":"Familial Mediterranean fever.","volume":"351","author":"Ben-Chetrit","year":"1998","journal-title":"Lancet"},{"key":"R20-3-20210207","first-page":"1362","article-title":"Interferon-alpha as a treatment modality for colchicine-resistant familial Mediterranean fever.","volume":"35","author":"Tweezer-Zaks","year":"2008","journal-title":"J Rheumatol"},{"key":"R21-3-20210207","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3899\/jrheum.100718","article-title":"Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine.","volume":"38","author":"Ozen","year":"2011","journal-title":"J Rheumatol"},{"key":"R22-3-20210207","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S1097-2765(03)00056-X","article-title":"Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis.","volume":"11","author":"Chae","year":"2003","journal-title":"Mol Cell"},{"key":"R23-3-20210207","first-page":"S99","article-title":"Treatment options in colchicine resistant familial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents.","volume":"24","author":"Seyahi","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"R24-3-20210207","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s004310050677","article-title":"Familial Mediterranean fever in children: report of a large series and discussion of the risk and prognostic factors of amyloidosis.","volume":"156","author":"Saatci","year":"1997","journal-title":"Eur J Pediatr"},{"key":"R25-3-20210207","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2350-5-4","article-title":"Amyloidosis in familial Mediterranean fever patients: correlation with MEFV genotype and SAA1 and MICA polymorphisms effects.","volume":"5","author":"Medlej-Hashim","year":"2004","journal-title":"BMC Med Genet"},{"key":"R26-3-20210207","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00296-006-0188-2","article-title":"Successful treatment of nephrotic syndrome due to FMF amyloidosis with azathioprine: report of three Turkish cases.","volume":"27","author":"Sayarlioglu","year":"2006","journal-title":"Rheumatol Int"},{"issue":"suppl 1","key":"R27-3-20210207","first-page":"1","article-title":"Successful treatment of renal AA amyloidosis in familial Mediterranean fever with pegylated alpha-2a interferon.","volume":"75","author":"Vandecasteele","year":"2011","journal-title":"Clin Nephrol"},{"key":"R28-3-20210207","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1056\/NEJMoa065644","article-title":"Eprodisate for AA Amyloidosis Trial Group. Eprodisate for the treatment of renal disease in AA amyloidosis.","volume":"356","author":"Dember","year":"2007","journal-title":"N Engl J Med"},{"key":"R29-3-20210207","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1002\/art.11163","article-title":"Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy.","volume":"48","author":"Gottenberg","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R30-3-20210207","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.amjmed.2005.01.028","article-title":"Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.","volume":"118","author":"Fernandez-Nebro","year":"2005","journal-title":"Am J Med"},{"key":"R31-3-20210207","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/01.rhu.0000128856.13595.eb","article-title":"Infliximab treatment of familial Mediterranean fever and its effect on secondary AA amyloidosis.","volume":"10","author":"Metyas","year":"2004","journal-title":"J Clin Rheumatol"},{"key":"R32-3-20210207","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/rheumatology\/kel250","article-title":"Clinical improvement with infliximab in a child with amyloidosis secondary to familial Mediterranean fever.","volume":"45","author":"Yuksel","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"R33-3-20210207","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00296-008-0616-6","article-title":"Coexistence of familial Mediterranean fever and psoriasis in a patient with seronegative spondyloarthropathy.","volume":"29","author":"Bodur","year":"2008","journal-title":"Rheumatol Int"},{"key":"R34-3-20210207","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/00062752-200001000-00012","article-title":"Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states.","volume":"7","author":"Urieli-Shoval","year":"2000","journal-title":"Curr Opin Hematol"},{"key":"R35-3-20210207","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/76216","article-title":"Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis.","volume":"6","author":"Yan","year":"2000","journal-title":"Nat Med"},{"key":"R36-3-20210207","doi-asserted-by":"crossref","first-page":"25781","DOI":"10.1074\/jbc.M001235200","article-title":"The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells.","volume":"275","author":"Tanaka","year":"2000","journal-title":"J Biol Chem"},{"key":"R37-3-20210207","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1056\/NEJM200010053431412","article-title":"Treatment of the nephrotic syndrome with etanercept in patients with the tumor necrosis factor receptor-associated periodic syndrome.","volume":"343","author":"Drewe","year":"2000","journal-title":"N Engl J Med"}],"container-title":["JCR: Journal of Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RHU.0b013e31823682f5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:56:31Z","timestamp":1620957391000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00124743-201110000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/rhu.0b013e31823682f5","relation":{},"ISSN":["1076-1608"],"issn-type":[{"value":"1076-1608","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}